Search

Reset

Searching with a thematic focus on Health, HIV and AIDS, HIV and AIDS treatment and care, Trade Policy, Intellectual Property Rights

Showing 11-20 of 21 results

Pages

  • Document

    Impact of patents on access to HIV/AIDS drugs in developing countries

    Center for International Development, Harvard University, 2002
    This paper uses sales data on HIV/AIDS drugs in a sample of 34 low and middle income countries between 1995 and 1999 to assess empirically the impact of patents on unsubsidized access to a new drug therapy.There can be two possible effects of patents on access to new drugs in developing countries.
  • Document

    Implications of WTO/TRIPS in East Africa : with special emphasis on pharmaceutical patents

    Economic and Social Research Foundation, Tanzania, 2002
    What has the impact of the TRIPs agreement been in East Africa? This study examines how patent protection relates to the overall promotion and protection of human rights, and socio-economic rights, in particular. The author concentrates on pharmaceutical patent protection and the new life saving drugs that should be available for treatment of HIV/AIDS in the region.
  • Document

    UK working group on increasing access to essential medicines in the developing world: Policy recommendations and strategy

    Department for International Development, UK, 2002
    This report of the UK Working Group on Increasing Access to Essential Medicines in the Developing World proposes that pharmaceutical companies provide drugs at near to cost price for HIV/AIDS, TB and malaria to the poorest countries.
  • Document

    WTO TRIPS agreement and its implications for access to medicines in developing countries

    Commission on Intellectual Property Rights, 2002
    This detailed issue briefing examines TRIPS in light of the Doha Declaration which mandates that TRIPS be interpreted in a manner that supports public health interests and promotes access to medicines.The study accepts the consensus of experts that developing countries should make use of policy options such as compulsory licensing and parallel importation to increase the supply of low-price med
  • Document

    AIDS: the undeclared war

    Stakeholder Forum, 2001
    Identifying the key issues relating to the war on HIV / AIDS as access to medication, cultural factors, lack of knowledge and resource short-fall this paper discusses broad areas of change needed to break current trends.The author goes on to suggest some more detailed policy responses for governments, ngos, the private sector and international institutions placing HIV /AIDS in the context of th
  • Document

    Post-TRIPS options for access to patented medicines in developing countries

    Commission on Macroeconomics and Health, WHO, 2001
    Since developing countries spend a large percentage of their private household health expenditures on drugs, affordability of patented medicines is particularly important.
  • Document

    Implausible denial: why the drug giants' arguments on patents don't stack up

    Oxfam, 2001
    This paper sets out the counter-arguments to Oxfam’s demand that patent protection should take into account national economic and health circumstances, and explains why Oxfam believes they are unconvincing.Criticisms and recommendations:Whilst patents play an important role in generating incentives for research and development (R&D), the super-profits which patents generate are c
  • Document

    Drug companies vs. Brazil: the threat to public health

    Oxfam, 2001
    The access of impoverished Brazilians to essential medicines, including those required for treatment of HIV/AIDS, is under threat.
  • Document

    World Trade Organisation agreements: implications for equity and health in Southern Africa

    EQUINET: Network for Equity in Health in Southern Africa, 2000
    This paper investigates the consequences of WTO agreements relating to health, and primarily the TRIPS agreement on health care and drug access for Southern African Development Community (SADC) countries.The paper provides a brief review of GATT /WTO and WTO agreements relating to health.
  • Document

    Encouragement of new clinical drug development: the role of data exclusivity

    International Federation of Pharmaceutical Manufacturers Associations, 2000
    Paper asserts that for the pharmaceutical industry to invest the billions of dollars, Euros, yen, etc. in these highly risky health care solutions, intellectual property protection is essential. However, patent and trade-mark protections are not the entire story.

Pages